Gapping down
In reaction to disappointing earnings/guidance: BAMM -4.8%
Select metals/mining stocks trading lower: GFI -2%, AU -1.9%, MT -1%, BHP -0.9%, RIO -0.8%
Select oil/gas related names showing early weakness: SD -1.6%, STO -1.3%, RDS.A -1.1%, SDRL -0.9%, BP -0.7%
Other news: MCP -24.4% (WSJ details that Molycorp (MCP) is expected to skip its June 1 debt payment), MRTX -20.8% (presented at ASCO, initial data from ongoing expansion study of MGCD265 -- also downgraded to Hold at Brean Capital), CLVS -8.6% (preented at ASCO, Phase 2 studies of rucaparib in ovarian cancer and Rociletinib (CO-1686) Phase 2 study results)
Analyst comments: ACAT -2% (downgraded to Underperform from Market Perform at BMO Capital), GSBD -1.4% (downgraded to Market Perform from Outperform at Wells Fargo), HES -0.8% (downgraded to Hold from Buy at Deutsche Bank
)
In reaction to disappointing earnings/guidance: BAMM -4.8%
Select metals/mining stocks trading lower: GFI -2%, AU -1.9%, MT -1%, BHP -0.9%, RIO -0.8%
Select oil/gas related names showing early weakness: SD -1.6%, STO -1.3%, RDS.A -1.1%, SDRL -0.9%, BP -0.7%
Other news: MCP -24.4% (WSJ details that Molycorp (MCP) is expected to skip its June 1 debt payment), MRTX -20.8% (presented at ASCO, initial data from ongoing expansion study of MGCD265 -- also downgraded to Hold at Brean Capital), CLVS -8.6% (preented at ASCO, Phase 2 studies of rucaparib in ovarian cancer and Rociletinib (CO-1686) Phase 2 study results)
Analyst comments: ACAT -2% (downgraded to Underperform from Market Perform at BMO Capital), GSBD -1.4% (downgraded to Market Perform from Outperform at Wells Fargo), HES -0.8% (downgraded to Hold from Buy at Deutsche Bank
)